Nosebleed

XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps

Retrieved on: 
Friday, March 15, 2024
Nosebleed, Research, Polyp (medicine), Vanderbilt University, Sciatica, Fluticasone, Education, Drainage, Disease, Incidence, Headache, Inflammation, Patient, Conditional sentence, Chronic obstructive pulmonary disease, Sinusitis, CRS, Standard of care, Quality of life, Migraine, Nasal cavity, Ear, ENT, Service, MPH, Nose, OPTN, FDA, Frustration, Food, Pharmaceutical industry

YARDLEY, Pa., March 15, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the U.S. Food and Drug Administration (FDA) has approved XHANCE® (fluticasone propionate) nasal spray for the treatment of chronic rhinosinusitis without nasal polyps in patients 18 years of age and older.

Key Points: 
  • Chronic sinusitis (also called “chronic rhinosinusitis” or “CRS”) is one of the most common chronic diseases, affecting approximately 30 million adults in the United States.
  • Research shows that the disease impairs quality of life to a similar degree as other serious chronic conditions, such as chronic obstructive pulmonary disease, sciatica, or migraine.
  • Chronic sinusitis is also one of the most common diagnoses in adult outpatient medicine.
  • Chronic sinusitis is diagnosed in approximately 10 million outpatient visits, of which approximately 70% result in antibiotic prescriptions, and leads to more than 600,000 surgeries annually.

Internist Shirin Peters, M.D. of Bethany Medical Clinic, Shares Top Tips for the Challenges of Winter Allergies

Retrieved on: 
Thursday, February 15, 2024
Other Consumer, Home Goods, Women, Other Health, Seniors, Retail, Teens, Pets, Parenting, Men, Children, Baby, Maternity, Family, Consumer, Veterinary, General Health, Other Retail, Health, Allergy, Pet, Atmosphere, Dust, Dry, Polyp (medicine), Diet, Sneeze, Inflammation, Filter (signal processing), Rash, Skin, HEPA, Risk, Honey, Allergen, Bacteria, MITES, Common, Nosebleed, Rosacea, Arm, Asthma, Zinc acetate, Nose, Immune system, Vaccine

has identified at-home recommendations to combat winter allergy symptoms, helping allergy sufferers manage triggers, ease concerns, and avoid future flare-ups.

Key Points: 
  • has identified at-home recommendations to combat winter allergy symptoms, helping allergy sufferers manage triggers, ease concerns, and avoid future flare-ups.
  • “Many associate seasonal allergies just with spring but winter presents a different challenge to allergy sufferers.
  • Moreover, simple lifestyle changes and at-home tips can help manage symptoms and bring some relief during these cooler months,” says Dr. Peters, with Bethany Medical Clinic.
  • Dr. Peters shares preventative measures to decrease your chances of winter and indoor allergies and lower your risk of developing sinusitis and nasal polyps.

Eton Pharmaceuticals Announces Commercial Availability of Ultra-Rare Disease Product Nitisinone Capsules

Retrieved on: 
Friday, February 2, 2024
Partnership, Conjunctivitis, Medicine, Inflammation, Vitamin, Thrombocytopenia, Immune system, Tyrosine, Patient, Light, Nosebleed, Intellectual disability, Itch, Ageing, Diet, Keratitis, Skin, Pharmacy, Tongue, Rash, DSM-IV codes, Allergy, Blood, Leukopenia, Photophobia, Mouth ulcer, Phenylalanine, Erythroderma, Tell, Insurance, Face, Breast milk, Plasma, Nursing

DEER PARK, Ill., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing, acquiring, and commercializing products to address unmet needs in patients suffering from rare diseases, today announced the commercial availability of Nitisinone Capsules for the treatment of hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine. Please see important safety information below. Tyrosinemia type 1 is an ultra-rare condition that is estimated to impact fewer than 500 patients in the United States.

Key Points: 
  • We believe that our existing commercial infrastructure and strong patient support services should help us capture a meaningful percentage of the estimated $50 million annual Nitisinone market,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals.
  • Nitisinone Capsules are available exclusively through Optime Care, a specialty pharmacy dedicated to helping patients with rare diseases manage their conditions.
  • Optime Care will administer the Eton Cares Program in partnership with Eton Pharmaceuticals.
  • To report a suspected adverse event related to Nitisinone, contact Eton Pharmaceuticals, Inc. at: 1-855-224-0233 or the US Food and Drug Administration at www.fda.gov/medwatch or call 1-800-FDA-1088.

Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology: In Practice

Retrieved on: 
Thursday, January 18, 2024
Senior, Chronic pain, Patient, Sciatica, Ear, Incidence, Polyp (medicine), ENT, Nosebleed, Sinusitis, Doctor of Pharmacy, Migraine, Randomness, Heart, OPTN, Quality of life, Medicine, Nose, Journal, Disease, Pressure, Drainage, FDA, Inflammation, MPH, Headache, Fluticasone, Pharmaceutical industry

YARDLEY, Pa., Jan. 18, 2024 (GLOBE NEWSWIRE) --  Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced peer-reviewed publication of results from both ReOpen1 and ReOpen2 in the Journal of Allergy and Clinical Immunology: In Practice1.

Key Points: 
  • The ReOpen program evaluated XHANCE for treatment of adults with chronic sinusitis (chronic rhinosinusitis).
  • “Patients with chronic sinusitis often suffer for years and may use multiple over-the-counter treatments in a search for ways to alleviate their symptoms.
  • Chronic sinusitis is also common: data suggests it is one of the top diagnoses in adult outpatient physician visits.
  • The safety profile and tolerability of XHANCE for patients in the ReOpen trials was generally consistent with its currently labeled safety profile.

Octapharma to present clinical and scientific data that advances our understanding and treatment of bleeding disorders at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD), which takes place in Frankfurt, Ge

Retrieved on: 
Wednesday, January 17, 2024
Factor VIII, Senior, Octapharma, Patient, Research, Nosebleed, SLAM, VWD, Trial of the century, Pharmaceutical industry

The study shows that wilate® prophylaxis is highly effective at reducing bleeding rates in children and adults with all types of VWD and across examined bleeding sites.

Key Points: 
  • The study shows that wilate® prophylaxis is highly effective at reducing bleeding rates in children and adults with all types of VWD and across examined bleeding sites.
  • The results provide compelling evidence for the use of regular prophylaxis in people with VWD.
  • "The new data from the WIL-31 study provide strong evidence for the use of wilate® prophylaxis in people with all types of VWD.
  • In such instances, indirect treatment comparisons can be used to compare the effects of different treatments.

uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease

Retrieved on: 
Tuesday, December 19, 2023
CSF, Patient, Nosebleed, Cure, Risk, Șaeș, Interest, Pulmonary embolism, PIN, Depression, FRCP, Headache, TMS, CHDI, Brain, Neurofilament, SAE, Clinical trial, TFC, Natural history, Event, Inflammation, Hypothermia, AFL, University College London, Biomarker, Back pain, Suicidal ideation, Central nervous system, Frasier, Deep vein thrombosis, UCL, Pharmaceutical industry

The U.S. study consists of a blinded 12-month core study period followed by unblinded long-term follow-up of five years for treated patients.

Key Points: 
  • The U.S. study consists of a blinded 12-month core study period followed by unblinded long-term follow-up of five years for treated patients.
  • Six patients were treated with AMT-130 in the initial low-dose cohort and seven patients were treated in the subsequent high-dose cohort.
  • The cohort includes 31 patients that met the uniQure clinical trial inclusion criteria of Total Functional Capacity, Diagnostic Classification Level and minimum striatal volumes.
  • In mid-2024, uniQure expects to present another clinical update from the ongoing Phase I/II studies of AMT-130, including additional follow-up data from the treated patients in the U.S. and European trials.

VEGZELMA® (bevacizumab-adcd) receives preferred formulary status with Ventegra® for commercially insured patients

Retrieved on: 
Monday, December 11, 2023
Urine, Reproduction, Skeleton, Headache, PSA, Kidney, Erythroderma, Patient, Pharmacy, Birth, Nephrotic syndrome, MBA, Cancer, Miscarriage, Safety, Incidence, VTE, Bevacizumab, Corneal opacity, Wound healing, VEGFR2, Gastrointestinal perforation, Hemoptysis, Female, Fetus, CHF, Celltrion, Pharming, Necrotizing fasciitis, Heart failure, Fistula, Risk, Tracheoesophageal fistula, Bleeding, Organogenesis, Partnership, Rhinitis, Hypertension, Primary ovarian insufficiency, Back pain, Pregnancy, Glioblastoma, PRES, Nosebleed, Skull, FDA, ATE, VEGF, MBM, Hypertensive encephalopathy, Toxicity, Nursing, Pharmaceutical industry, Birth control, Dietary supplement, Proteinuria

Ventegra's proprietary formulary program (which includes Formulary Shield and the Ventegra Specialty Inclusion Program) is available for access by more than 400 clients and 13 million members/patients that are enrolled with Ventegra.

Key Points: 
  • Ventegra's proprietary formulary program (which includes Formulary Shield and the Ventegra Specialty Inclusion Program) is available for access by more than 400 clients and 13 million members/patients that are enrolled with Ventegra.
  • Gastrointestinal Perforations and Fistula: Discontinue for gastrointestinal perforations, tracheoesophageal fistula, grade 4 fistula, or fistula formation involving any organ.
  • Surgery and Wound Healing Complications: In patients who experience wound healing complications during VEGZELMA treatment, withhold VEGZELMA until adequate wound healing.
  • Do not administer VEGZELMA for at least 28 days following a major surgery, and until adequate wound healing.

Excellence and Innovation: Mixhalo Takes Home Two Prestigious AV Awards

Retrieved on: 
Tuesday, November 28, 2023
Nosebleed, SAN, All-star game, Buffalo Sabres, NASCAR, FC Dallas, Culture, T-Mobile, Final call, Product management, Toyota Stadium (Texas), Partnership, Home Run Derby, Athlete, Toyota Stadium, Tennis, T-Mobile Park, Los Angeles FC, LAFC, L-Acoustics, Mobile phone, Nightclub, Music, Sport

SAN FRANCISCO, Nov. 28, 2023 /PRNewswire-PRWeb/ -- Mixhalo, the ultra-low latency networking technology that streams high-fidelity audio to fans at live events in real-time, is thrilled to announce it has been awarded the prestigious Audio Technology of the Year and Event Technology of the Year awards at this year's AV Awards.

Key Points: 
  • Being honored at the AV Awards is a testament to the incredible work and dedication of the entire Mixhalo team.
  • The AV Awards, held earlier this month in London, is the unrivaled badge of excellence for the audio-visual industry and the benchmark for the highest possible professional standards and best practices.
  • "Being honored at the AV Awards is a testament to the incredible work and dedication of the entire Mixhalo team," said Corey Laplante, President & COO of Mixhalo.
  • -- In April 2023, NASCAR announced that it would become the first motorsports organization to offer Mixhalo features through its own app.

SourceMark Medical Partners with NasaClip to Streamline Nosebleed Treatment

Retrieved on: 
Wednesday, October 25, 2023
MBE, FDA, Minority business enterprise, US Foods, Patient, Partnership, Nosebleed, Birth control, Nursing

FRANKLIN, Tenn. , Oct. 25, 2023 /PRNewswire/ -- SourceMark Medical, a US medical device company and certified Minority Business Enterprise (MBE), announced a supplier partnership today with NasaClip, an easy-to-use nosebleed rescue device available in adult and pediatric sizes.

Key Points: 
  • FRANKLIN, Tenn. , Oct. 25, 2023 /PRNewswire/ -- SourceMark Medical, a US medical device company and certified Minority Business Enterprise (MBE), announced a supplier partnership today with NasaClip, an easy-to-use nosebleed rescue device available in adult and pediatric sizes.
  • "We're thrilled to partner with SourceMark and expand provider access to NasaClip," said Dr. Elizabeth Clayborne, founder and CEO of NasaClip.
  • "NasaClip offers an innovative solution to treat patients with nosebleeds quickly and more effectively with minimal provider intervention," said Dan Blucher, CEO of SourceMark Medical.
  • "We're pleased to partner with NasaClip to improve patient outcomes while cutting nosebleed treatment time and costs."

Combating Nosebleeds: Tips for This Year's Cold/Flu Season

Retrieved on: 
Wednesday, October 25, 2023
Allergy, ENT, Research, Nosebleed, Bleeding, Tissue, Blood, Neck, Parent, Nose, Petroleum jelly, Amazon

CHARLOTTE, N.C., Oct. 25, 2023 /PRNewswire/ -- 60 million people across the United States will experience nosebleeds this cold/flu winter season, most likely to occur when cold weather and indoor heating dry out nasal passages.* Research also shows that approximately 90% of kids will also get nosebleeds as well, making it essential to be prepared when they occur. A new solution has just hit the market to combat this challenge – it doesn't rely on the traditional 5-10 tissues method – and absorbs up to 10x more blood than tissues. Nampons Kids™ – a new, first of its kind nasal plug – is now available to tackle this common issue with ease and relief for parents.

Key Points: 
  • * Research also shows that approximately 90% of kids will also get nosebleeds as well, making it essential to be prepared when they occur.
  • Nampons Kids™ – a new, first of its kind nasal plug – is now available to tackle this common issue with ease and relief for parents.
  • "Throughout my life, as a regular allergy and sinus sufferer, I dealt with constant nosebleeds.
  • Use a Nasal Plug (Nampons): Nasal plugs like Nampons™ are designed to quickly and effectively stop nosebleeds.